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SUMMARY
Target-based approaches for human African trypanosomiasis (HAT) and related parasites can be a valuable route for drug
discovery for these diseases. However, care needs to be taken in selection of both the actual drug target and the chemical
matter that is developed. In this article, potential criteria to aid target selection are described. Then the physiochemical
properties of typical oral drugs are discussed and compared to those of known anti-parasitics.
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INTRODUCTION
Human African trypanosomiasis (HAT) is endemic
in sub-Saharan Africa, wheremillions are at risk from
this disease. The disease, caused by the protozoan
parasites Trypanosoma brucei gambiense and Trypa-
nosoma brucei rhodesiense, has two stages; stage 1 is the
peripheral infection, which has non-speciﬁc symp-
toms and stage 2 occurs when the parasite enters the
central nervous system (CNS). HAT is fatal unless
treated. The current treatments for stage 1 infection
are suramin and pentamidine. For stage 2, the
therapeutic options are melarsoprol, eﬂornithine
and the recent combination therapy NECT (nifurti-
mox and eﬂornithine) (Brun et al. 2011). The current
drugs available for treating HAT are inadequate, due
to toxicity and poor eﬃcacy. There are also problems
with treatment failures for melarsoprol, although it
is not known if this is due to resistance (Wilkinson
and Kelly, 2009). In addition, the current treatments
are inappropriate for a rural setting with poor
facilities as they all require parenteral administration.
There is need for new treatments for HAT, for
the reasons given above, but also with the aim of
elimination and eradication of this disease.
Recently there has been a marked decrease in
numbers of cases and the agenda has turned more
to elimination and eradication. Currently there are
about 10 000 recorded cases per year. However, the
true number of people aﬄicted by this disease is
estimated to be much higher due to under-reporting;
probably 30 000 cases per year (Brun et al. 2011).
Furthermore, it is appropriate to take warnings from
history, where there has been a huge change in the
number of cases; during themiddle of the last century
the disease was nearly eliminated, but was resurgent,
and, by the end of the last century, there were an
estimated 450 000 people aﬀected (Barrett, 1999,
2006; Brun et al. 2011).
There have been very few drug discovery and
development programmes for HAT. Recently, how-
ever, there has been an increased eﬀort in drug
discovery for HAT and other neglected tropical
diseases due to the generosity of organizations
such as the Wellcome Trust, the Bill and Melinda
Gates Foundation and the organization Drugs
for Neglected Diseases (DNDi). This has led to
increased understanding of the drug discovery
processes for diseases such asHATand infrastructure
put into place for drug discovery.Given this impetus,
it is now important to make sure that new medicines
are delivered for HAT.
Signiﬁcant recent approaches include a diamidine
developed by Tidwell’s group, which was taken as
far as phase 3 clinical trials, but unfortunately had
to be withdrawn (Barrett and Croft, 2012). Two new
molecules have been moved into clinical trials by
DNDi. These compounds are the nitro heterocycle
fexinadazole and the oxaborole SCYX-7158. This is
an exciting new development.
Drug discovery for neglected tropical diseases,
such as HAT, is being conducted using both target-
based and phenotypic approaches (Gilbert et al.
2011). In this article, approaches to selection of
targets andmolecules for target-based drug discovery
are discussed. Critical to the selection of targets and
molecules is the Target Product Proﬁle.
TARGET PRODUCT PROFILE
Target product proﬁles (TPP) deﬁne the require-
ments for a drug molecule to be clinically applicable.
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These include features such as the acceptable route
for dosing the compound, the duration of treatment,
the patient population, cost and acceptable range
of toxicity. These are deﬁned by clinicians and public
health agencies who understand the clinical needs
of the patients (Wyatt et al. 2011). An example of a
TPP forHAT, deﬁned byDNDi is shown inTable 1.
The TPP needs to be regularly reviewed, as it may
well change due to other treatment options becoming
available, changes in the clinical situation or drug
resistance to existing compounds becoming a signiﬁ-
cant issue.
The target product proﬁle will inform drug
discovery projects from the very start. This helps
to deﬁne both the molecular target and chemical
matter that is developed during a drug discovery
programme.
Thus, the molecular target must be able to fulﬁl
the TPP. For example, in the case of HAT, the
molecular target must: (1) be essential for viability
of the parasite in the human host; (2) have a rapid
cidal eﬀect when inhibited and (3) be amenable to
inhibition by small drug-like molecules that have
the correct physiochemical properties to be orally
bioavailable and cross the blood-brain barrier.
Similarly, the molecules that are for screening
must be capable of fulﬁlling the TPP once optimized
through the hits to lead and lead optimization phase.
In the case of HAT for example, there is a need for
orally bioavailable compounds; thus compounds that
are selected should have the appropriate physico-
chemical and pharmacokinetic properties for oral
bioavailability.
Therefore in target-based drug discovery, in order
to fulﬁl the TPP, both the molecular target and the
chemical matter must be carefully selected, and their
selection actually go hand-in-hand.
SELECTION OF DRUG TARGETS
The selection of a target for drug discovery is of
key importance. A target is considered truly validated
when it is in the clinic for treating human diseases.
In the case of HAT (and the other kinetoplastid
diseases), there is really only one target fully validated
to this extent, ornithine decarboxylase. This is
the target of the drug eﬂornithine (DFMO), which
is used for the treatment of HAT. There are
other drug targets which have signiﬁcant levels of
validation though; for example, protein farnesyl-
transferase (Eastman et al. 2006; Gillespie et al.
2007) and S-adenosylmethionine decarboxylase
(Jacobs et al. 2011; Velez et al. 2013). Another target
for HAT is N-myristoyltransferase (NMT) that we
have pursued at the Drug Discovery Unit (DDU) at
the University of Dundee (Frearson et al. 2010;
Brand et al. 2012).
Current methods for target-based drug discovery
usually involve screening diverse or focused libraries
against the molecular target. The hits are then
characterized and optimized through rounds of
design, synthesis and testing against protein and
cell. The testing usually includes assays for potency,
selectivity and pharmacokinetic properties. In terms
of target validation, it is important to prove that the
compounds are acting on-target, and that it is
inhibition (or modulation) of the target that is
causing the death of the parasite. The compounds
are then assayed in animal models of infection. It is
only at this stage that it becomes clear if the proposed
drug target has a reasonable degree of validation. In
other words, a very considerable amount of time and
resource will be consumed before there is reasonable
evidence that the target chosen is a valid drug target.
Therefore it is important to choose drug targets very
Table 1. Example of a new stage 1+2 target product proﬁle (produced by DNDi)
Ideal Acceptable improvement to current stage 2
Eﬀective against stages 1 and 2 Eﬀective against stages 1 and 2, but only used against stage 2.
Eﬀective against infection due to T. b. gambiense
and T. b. rhodesiense.
Eﬀective against infection due to T. b. gambiense only.
Clinical eﬃcacy >95% at 18 months follow-up
Eﬀective in melarsoprol-refractory patients
<0·1% drug related mortality <1% drug related mortality
Safe during pregnancy, for breastfeeding women
and children.
Adult and paediatric formulations
No monitoring for adverse events required. Weekly simple lab testing (ﬁeld testing)
<7 days p.o. q.d. 10 days p.o. upto tid.
<7 days i.m. q.d. 10 days i.m. q.d.
Stability in zone 4 for >3 years Stability in zone 4 for >12 months
Cidal
Multitarget Unique target (but not through uptake via
P2-transporter only).
<30E/ course (drug cost) <100E/ course
<220E/ course OK if very good on other criteria.
http://www.dndi.org/diseases-projects/diseases/hat/target-product-proﬁle.html
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carefully at the outset of a drug discovery pro-
gramme.
TRAFFIC LIGHT SYSTEM
At the DDU at the University of Dundee, we have
carried out target-based drug discovery programmes
against HAT. We use 6 criteria to help us select
molecular targets to enter ourdrugdiscoverypipeline.
The criteria are: essentiality, druggability, assayabil-
ity, resistance potential, toxicity potential and struc-
tural information. To help compare between the
diﬀerent targets, we have established a ‘traﬃc light’
scoring system for the diﬀerent criteria, as reported
(Frearson et al. 2007; Wyatt et al. 2011). Essentially
each criterion is given a green, amber or red score,
according to a number of deﬁnitions, which are
summarized in Table 2. This provides a rapid visual
method to assess an individual target and to compare
between diﬀerent potential drug targets. The assign-
ment of a ‘red’ score does not necessarily mean that
this is a no-go situation; it could just indicate a lack
of information. There are also clear cases for a no-go
decision – for example, if it is shown that the target is
not essential for survival of the parasite.
Essentiality
When designing a compound against a pathogen, it is
important that the drug target is essential. This can
be assessed both genetically and chemically. Genetic
validation can be carried out in a number of ways.
In many organisms this can be a complex process.
In the case of T. brucei, there are more genetic tools
available than with many other organisms; however,
even in the case of this organism, genetic validation
can still be problematic. In the case of T. brucei, it
is possible to carry out RNAi to knock down the
enzyme and see if there is a phenotypic response
(Motyka and Englund, 2004; Ullu et al. 2004).
A more rigorous method is to carry this out by
knockout studies (Barrett et al. 1999; Beverley, 2003).
Whilst knockdown or knockout of a gene in
cell culture can prove that a gene is essential to the
viability of the parasite, it does not necessarily
mean that it is a good drug target. There can be
issues with druggability (see below). Other reasons
that the genetic validation may not be suﬃcient
include by-pass mechanisms that can occur in vivo.
Furthermore, during knockout experiments the
protein is removed. The protein may have a vital
‘structural’ role due to interactions with other
proteins, rather than the reaction products being
vital to the parasite. A further complication with
genetic validation is the rate of kill. So for example,
the enzyme trypanothione synthase is genetically
essential for the viability of the parasite. However,
genetic knockdown/knockout of the enzyme leads to a
slow rate of killing ofT. brucei, meaning an inhibitory
drug concentration would have to be maintained for
Table 2. Criteria for molecular targets developed at the DDU (Frearson et al. 2007; Wyatt et al. 2011)
Green Amber Red
Essentiality Genetic and chemical validation
that the target is essential for
survival of the organism
Genetic or chemical validation that
the target is essential for survival
of the organism
No or weak genetic or chemical
validation that the target is
essential for survival of the
organism
Druggability Drug-like, small molecule
inhibitors are known and there
is a druggable active site (clinical
activity within the target family)
Drug-like, small molecule
inhibitors are known or the active
site is potentially druggable
No drug-like, small molecule
inhibitors are known and the
active site is not druggable
Assayability Robust assay in plate format
amenable to high-throughput
screening developed and active
protein supply assured within
appropriate time-lines
In vitro assay exists, development
into robust, plate format feasible,
but not yet achieved
No in vitro assay developed and/




Target has no known isoforms
within the same species and is
not subject to escape from
inhibition.
Target has isoforms within same
species or may be subject to
escape from inhibition.
Target has multiple gene copies
or isoforms within same species




No human homologue of the
target present, or the human
homologue is known to be non-
essential and inhibition of this
shows no eﬀect on the human
host
Human homologue of the target is
present, but evidence (structural
or chemical) that selective
inhibition is possible
Human homologue of the target






Ligand-bound structure of target
or ligand in closely related
homologue available at high
resolution (<2·3 Å)
Structure without ligand available
and/or poor resolution (>2·3 Å)
or opportunity to build a good
homology model (high sequence
homology to homologue)
No structure of target or closely
related homologue
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an extended period of time before any therapeutic
eﬀect is likely to be observed (Spinks et al. 2012).
Druggability
It is important that it is possible to obtain drug-like
inhibitors of the enzyme active site that have the
potential to fulﬁl the TPP. For example, if the TPP
requires an oral drug, the binding pocket of the
molecular target should have a good balance of
polarity and hydrophobicity, and also present a
reasonably-sized pocket. The pocket should not be
too large, as this will probably require a large
molecule to obtain good inhibition of the target.
Similarly, for a pocket that is too small it may be
diﬃcult to obtain an inhibitor with suﬃcient
selectivity and potency. This will mean that the
inhibitor (which will have complementarity in both
shape and charge distribution to the active site) is
more likely to have the properties required for an oral
drug (see below for more discussion). The best
evidence for druggability is that there is clinical
precedence for this target class. Whilst this level
of information is not available for most targets,
often there are literature reports of inhibitors or tool
molecules that inhibit the target or close homologues
of the target which guide target assessment. There are
also computational methods to assess druggability,
such as one produced at Dundee by Krasowski et al.
(2011). Recently it has been reported that fragment
screening is an eﬀective way to assess druggability
(Edfeldt et al. 2011).
Assayability
Developing robust assays, suitable for 384-well
format screening can be a time-consuming challenge.
There is now a large array of diﬀerent screening
platforms available and, for most enzymes, it is
possible to derive an appropriate assay. A more
signiﬁcant problem is actually obtaining soluble,
active proteins to carry out assays. Protein expression
can be very challenging and we have identiﬁed a
number of targets wewere interested in investigating,
but for which wewere unable to obtain soluble, active
proteins.
Resistance potential
Resistance is always going to be a problem with
anti-infectives. There are many diﬀerent ways by
which resistance can occur; for example, single point
mutations altering residues in the target, eﬄux
pumps, over-expression of the target, gene ampliﬁca-
tion of the target, inactivation of the drug. Some of
these are very diﬃcult to predict but, in some cases,
there are clear pathways available to resistance, such
as isoforms within the same organism. In the case of
many organisms it is possible to check this, through
bioinformatic analysis of the genomes.
Toxicity potential
Toxicity can arise from a number of diﬀerent causes.
Toxicity can occur if there is a human homologue of
the enzyme that is being targeted. It can be diﬃcult to
predict if compounds will inhibit both the pathogen
enzyme and human homologue. Occasionally even if
the pathogen and human enzymes have very similar
enzyme structures, it can be possible to obtain highly
selective inhibitors of one enzyme, for reasons that
are not well understood. For example, in the DDU
compounds were obtained that are very selective for
the leishmania protein kinase CRK3, although it has
a similar sequence in the active site to various human
protein kinases (Cleghorn et al. 2011). Nevertheless,
where there is a high level of similarity between
the active sites of pathogen and human homologues,
this should act as a signiﬁcant risk factor when sel-
ecting potential drug targets in the absence of other
information.
Toxicity can also arise from other unexpected
interactions of compounds with the human host.
Sometimes this can be deduced from the structure of
the compound; hence many organizations remove
potential toxic functionality (such as Michael accep-
tors) from their screening collections. Other toxicities
are not easy to predict, and are often only picked up
much later in the drug discovery process. Toxicity is
one of the most signiﬁcant reasons for attrition in the
drug discovery process (Kola and Landis, 2004;
Arrowsmith, 2011a, b).
Structural information
Whilst structural information on a protein (and
ideally a protein-ligand complex) is very helpful for
compound optimization for target-based pro-
grammes, it is not essential. Structural information
is at its most powerful when it is possible to obtain
co-crystal structures of the protein with inhibitors,
as this guides the design process. It can be even
more helpful if there is also a structure of the human
homologue (where applicable) to guide selective
inhibitor design. Therefore, although structural
information is not critical to target-based drug
discovery, it can be an extremely powerful tool to
move projects along.
PROPERTIES OF MOLECULES
In terms of drug discovery, although it is important
to have a good molecular target, it is equally
important to develop the molecules with the correct
properties to achieve the TPP. The TPP allows
criteria to be set for compounds for the diﬀerent
stages of the drug discovery programme in terms of
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potency, selectivity, pharmacokinetics and safety
pharmacology. Given that during the discovery of
a clinical candidate, the molecular weight and
lipophilicity are likely to increase (Nadin et al.
2012), this should be taken into account when
choosing the starting chemical library – compounds
must be amenable to increases both in lipophilicity
and molecular weight during optimization without
compromising developability.
The TPPs for the kinetoplastid diseases generally
require oral drugs. Lipinski deﬁned his famous
‘rule of 5 as a guide as to whether a molecule is in
the correct chemical space to be an orally bioavailable
compound (Lipinski et al. 1997). In his rules,
compounds should have a molecular weight of less
than 500, clogP <5, less than 5 hydrogen bond donors
and less than 10 hydrogen bond acceptors (Lipinski
et al. 1997). Current thinking suggests that we should
be even more stringent about the physicochemical
properties of molecules. Analysis of drug molecules
indicates for oral drugs, the average molecular weight
is 333 and the average clogP is 2·5 (Gleeson et al.
2011). LogP in particular appears to be correlated to a
number of developability issues, including toxicity,
metabolic instability and insolubility (Leeson and
Springthorpe, 2007; Hughes et al. 2008; Hann,
2011). Recent publications suggest an ideal clogP
value lies in the range of 1–3. In addition to clogP
and MW, analysis indicates that other criteria are
important in prospective drug candidates. (1) The
3-dimensionality is important in drug-molecules.
Thus the proportion of sp3 carbon atoms in a drug is
0·47 (Lovering et al. 2009). Analysis indicates that in
early drug discovery, the average proportion of sp3
carbon atoms is 0·36 and this gradually rises along the
drug discovery pathway. The 3-dimensionality helps
properties of molecules such as solubility by decreas-
ing planarity and gives access to more chemical
space. (2) The number of carbocyclic aromatic rings
impacts negatively on the developability of molecules
(Ritchie and MacDonald, 2009; Ritchie et al. 2011).
The number of carbocyclic aromatic rings is corre-
lated with lower solubility, higher logD, higher
plasma protein binding, hERG inhibition and
inhibition of some major cytochrome P450s (3A4,
2C9, 2C19). (3) For compounds required to reach the
CNS, there are additional criteria. Wager et al. at
Pﬁzer have carried out a thorough analysis of
properties of compounds that have CNS penetration
(Wager et al. 2010a,b). This suggested a number of
‘optimum’ values for a number of factors – for
example: clogP=2·8; MW=305; Polar surface area
(PSA)=45; HBD=1; pKa=8·4.
In addition to the physicochemical properties of
molecules, many research laboratories ﬁlter out
functional groups known to be chemically reactive
or toxic (Brenk et al. 2008). In some cases this is a
clear-cut decision. For example, acyl chlorides are too
unstable to be developed. In other cases, the decisions
about which groups to include and which to exclude
are less clear. Therefore, excluding certain functional
groups is a careful balancing act; excluding functional
groups can make the compounds ‘cleaner’, but
reduces the chemotypes covered. In some cases this
becomes a judgement call, balancing the risks of
certain chemical functionality against the risks of
restricting the chemical space covered in a library.
For example, nitro groups may be excluded due to
potential genotoxicity concerns, although some
drugs have aromatic nitro groups. It is important to
understand the risk inherent in certain types of
functional groups and to address this risk as early as
possible in the discovery process, if it is decided to
include these.
PROPERTIES OF CURRENT DRUGS USED FOR
TREATMENT OF KINETOPLASTID INFECTIONS
Interestingly, if the current drugs used for the
treatment of kinetoplastid diseases are analysed, it
is clear that not many of them are ideal from a
physicochemical perspective, given that the current
Table 3. Physicochemical properties of currently used drugs for kinetoplastid infections
Compound MW clogPa HBDb HBAb PSA RO5
Suramin 1297 2·2 12 23 468 N
Pentamidine 340 2·8 6 4 118 N
Melarsoprol 398 1·7 6 4 123 N
Eﬂornithine 182 −3·7 5 4 89 Y
Nifurtimox 273 −0·2 0 7 109 Y
Benznidazole 260 0·7 1 4 93 Y
Amphotericin B 924 −1·2 13 18 320 N
Miltefosine 408 6·0 0 4 56 N
Paramomycin 616 −3·0 18 20 347 N
Stibogluconatec 680 −3·5 8 17 276 N
Meglumine antimoniatec 366 7 9 N
a clogP was calculated using StarDrop™.
b HDB and HBA are given as deﬁned by Lipinski (Lipinski et al. 2001).
c The precise structures of stibogluconate and meglumine antimoniate are not known.
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Fig. 1. Current drugs used for the treatment of kinetoplastid infections.
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TPPs for the kinetoplastid infections require oral
drugs. Indeed most of the drugs are not orally
bioavailable and require parenteral administration,
as would be predicted by their physicochemical
properties (Table 3 and Fig. 1). The only orally
bioavailable drugs are nifurtimox, benznidazole
and miltefosine. The former two are compliant
with Lipinski’s rules and whilst miltefosine has a
logP value of >5, miltefosine is zwitterionic and
the clogD value is 1·5 which is well within the
Lipinski criteria. Eﬂornithine theoretically fulﬁls
Lipinski’s rules; however the compound is so
hydrophilic (clogP=−3·7) that it is very unlikely to
traverse membranes well by passive diﬀusion and is
actually given by intravenous infusion.
Interestingly melarsoprol, nifurtimox and eﬂor-
nithine are used for the treatment of stage 2 HAT,
suggesting that the compounds are blood-brain
barrier penetrants. Melarsoprol and nifurtimox are
not predicted to be blood-brain barrier penetrants
based on normal criteria as their polar surface areas
are too high (Kelder et al. 1999). Eﬂornithine has a
marginal level of PSA, but the negative clogP and
zwitterionic nature of the molecule suggest that it
is not likely to be passively permeable. The uptake
of these molecules is likely to be due to transporter-
mediated uptake, which is very diﬃcult to predict or
plan for.
Whilst clearly there are compounds that are
suitable as drug candidates that do not meet criteria
such as Lipinski’s rules, these mark the exception
rather than the rule and the exceptions are diﬃcult to
predict as they involve factors such as transporter-
mediated uptake. Therefore the physicochemical
properties of molecules should be taken into account
during the design process.
N-MYRISTOYLTRANSFERASE (NMT)
By way of example, in the DDU (University of
Dundee), in collaboration with others, we have
provided very strong validation of NMT as a drug
target for HAT (Frearson et al. 2010; Brand et al.
2012). I will brieﬂy summarize its validation process
below.
NMT is an enzyme found in all eukaryotic cells; its
function is co-translational modiﬁcation of a number
of proteins, byN-myristoylation of theirN-terminal
glycine atoms. NMT has been investigated as a
potential target for fungal diseases by a number of
companies; but, despite discovery of some very
potent inhibitors, none of these have been progressed
to market.
Within T. brucei, NMT has been genetically
validated initially by RNAi experiments by Price
et al. (2003), and then kinetically characterized by
Panethymitaki et al. (2006) in York. We set about
validation of NMT as a target inT. brucei. It was then
established that when NMT is knocked-down by
RNAi, the parasites are unable to establish an
infection in mice, adding further genetic validation
(Price et al. 2010). To obtain chemical validation,
at the DDU, we proﬁled a number of reported
inhibitors of fungal NMT against T. brucei NMT
(Brand et al. 2012); but none of these showed
signiﬁcant inhibition of the T. brucei enzyme. We
therefore carried out a high-throughput screen using
a 62000 compound diversity library (Brenk et al.
2008) from the DDU. This led to identiﬁcation of a
series of pyrazole sulphonamides as hit molecules,
with the most potent compound having an IC50 value
of 1·9 μM (Fig. 2). These were optimized to a potent
inhibitor, DDD85646 with an IC50 value of 0·002 μM
against T. brucei NMT and EC50 value of 0·002 μM
against the parasite. We were then able to show
that the compounds were active in rodent models of
infection, both forT. b. brucei (curative at 12·5 mg/kg
po bid for 4 days) and T. b. rhodesiense (curative at
50mg/kg po bid for 4 days).
In order to validate that these compounds were
acting against NMT, a number of experiments were
undertaken. These have been reported previously
(Frearson et al. 2010), but are summarized here to
show how they are important in validation of the
target. (1) It was possible to obtain a co-crystal
structure of the inhibitor DDD85646 with the
T. brucei NMT homologue, Leishmania major
NMT.This shows the inhibitor bound in the enzyme
active site, occupying the peptide binding pocket.
This is evidence that the compound can bind to the
enzyme and that it binds in the substrate binding
pocket. (2) We looked at a large number of inhibitors
of T. brucei NMT and compared them to inhibition
of parasite growth. There was a very good correlation
between inhibition of the enzyme and inhibition of
parasite growth, which is a good indication that
inhibition of TbNMT is responsible for the death of
the parasites. (3) The gene encoding for NMT was
over-expressed within the parasite T. brucei by about
5-fold. This gave rise to an 8-fold change in potency
Fig. 2. Compounds active against T. brucei NMT.
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from 2·1 to 17 nM. This indicates that the compounds
are inhibiting NMT and that cell death is due to
inhibition of NMT. (4) A further experiment was to
incubate the parasites with radio-labelled myristic
acid. This is incorporated into proteins through
myristoylation, which could be checked by SDS-
PAGE. When the experiment was repeated in the
presence of DDD85646, myristoylation is prevented
and no radio-labelled proteins could be detected.
This is good evidence that in cells, NMT inhibitors
prevent myristoylation of proteins.
Therefore, through a suite of experiments, we
have obtained good evidence that NMT is a valid
drug target for HAT (Frearson et al. 2010).
The target has been genetically validated through
RNAi both in cells and in amousemodel of infection.
We have demonstrated that our compounds
inhibit NMT through binding to the peptide binding
pocket of the enzyme. Inhibition of NMT prevents
myristoylation of proteins in cells and leads to
cell death of T. brucei. When dosed to mice orally,
at suﬃcient levels to give unbound blood levels
at EC99, these NMT inhibitors cure animal models
of HAT.
In terms of physicochemical properties, these
compounds are appropriate for oral bioavailability:
i.e. MW=495; cLogP=3·1; HBD=2; HBA=5.
However, DDD85646 does not have the correct
physicochemical properties for CNS penetration,
and indeed it is not active in a CNS model of
infection. Interestingly when we started this project,
there was a TPP for oral stage 1 compounds for HAT
but during the work on this project, the priority was
changed to requiring a TPP activity in the CNS stage
2 of infection. This demonstrates how TPPs can alter
and the eﬀect that they can have on the types of
molecule that are required for the indication.
CONCLUSION
Target-based drug discovery is possible for HAT
but careful selection of the molecular target must
be made. Often there is insuﬃcient information
available to be certain of how valid selected molecular
targets are at the beginning of a drug discovery
project. It is therefore important that the correct
biological experiments are carried out and tool
molecules prepared to validate the molecular
targets early in the project. These include genetic
validation experiments and mode of action exper-
iments with tool molecules to demonstrate that the
tool molecules are acting on target and it is through
inhibition of the target that they exert their anti-
parasitic activity. Thought must also be put into
selection of compounds for screening and the
compounds that are developed, to make sure that
they have the correct physicochemical and pharma-
cokinetic properties.
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